Why Is Apple Stock Not Joining the Broader Market Rally?
The S&P 500 has sprinted 4.92% higher so far in…
Sell
16
APVO Quote, Financials, Valuation and Earnings
Last price:
$3.08
Seasonality move
:
-25.73%
Day range:
$3.03 - $3.23
52-week range:
$2.81 - $485.37
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
0.01x
P/B ratio:
0.10x
Volume:
308.2K
Avg. volume:
4.7M
1-year change:
-99.19%
Market cap:
$2.1M
Revenue:
--
EPS (TTM):
-$1,596.48
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
APVO
Aptevo Therapeutics
|
-- | -$75.60 | -- | -98.86% | $21.00 |
|
ATNM
Actinium Pharmaceuticals
|
-- | -$0.36 | -100% | -7.24% | $5.00 |
|
NBY
NovaBay Pharmaceuticals
|
$3M | -$0.88 | 14.03% | -95.43% | $0.85 |
|
NNVC
Nanoviricides
|
-- | -$0.20 | -- | -26.67% | -- |
|
OGEN
Oragenics
|
-- | -- | -- | -- | $1.00 |
|
TOVX
Theriva Biologics
|
-- | -$0.43 | -- | -95.63% | $7.00 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
APVO
Aptevo Therapeutics
|
$3.08 | $21.00 | $2.1M | -- | $0.00 | 0% | 0.01x |
|
ATNM
Actinium Pharmaceuticals
|
$1.42 | $5.00 | $44.3M | -- | $0.00 | 0% | -- |
|
NBY
NovaBay Pharmaceuticals
|
$0.61 | $0.85 | $3.5M | -- | $0.00 | 0% | 0.16x |
|
NNVC
Nanoviricides
|
$1.40 | -- | $22.5M | -- | $0.00 | 0% | -- |
|
OGEN
Oragenics
|
$4.05 | $1.00 | $2.9M | -- | $0.00 | 0% | 1.30x |
|
TOVX
Theriva Biologics
|
$0.43 | $7.00 | $3.5M | -- | $0.00 | 0% | 0.33x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
APVO
Aptevo Therapeutics
|
-- | 1.757 | -- | -- |
|
ATNM
Actinium Pharmaceuticals
|
-- | -3.250 | -- | 9.03x |
|
NBY
NovaBay Pharmaceuticals
|
4.54% | -0.941 | 1.51% | 0.75x |
|
NNVC
Nanoviricides
|
-- | -0.642 | -- | -- |
|
OGEN
Oragenics
|
-- | -1.150 | -- | -- |
|
TOVX
Theriva Biologics
|
-- | -3.651 | -- | -- |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
APVO
Aptevo Therapeutics
|
-- | -$6.5M | -- | -- | -- | -$6.6M |
|
ATNM
Actinium Pharmaceuticals
|
-- | -$16.6M | -95.08% | -95.08% | -12769.14% | -$7.6M |
|
NBY
NovaBay Pharmaceuticals
|
$1.6M | -$2.7M | -334.47% | -461.38% | -44% | -$1.3M |
|
NNVC
Nanoviricides
|
-- | -$2.2M | -- | -- | -- | -$2M |
|
OGEN
Oragenics
|
-- | -$2M | -- | -- | -- | -$2.1M |
|
TOVX
Theriva Biologics
|
-- | -$4.4M | -- | -- | -- | -$4.8M |
Aptevo Therapeutics vs. Competitors
-
Which has Higher Returns APVO or ATNM?
Actinium Pharmaceuticals has a net margin of -- compared to Aptevo Therapeutics's net margin of -11511.11%. Aptevo Therapeutics's return on equity of -- beat Actinium Pharmaceuticals's return on equity of -95.08%.
Company Gross Margin Earnings Per Share Invested Capital APVOAptevo Therapeutics-- -$87.80 -- ATNMActinium Pharmaceuticals-- -$0.51 $36.4M -
What do Analysts Say About APVO or ATNM?
Aptevo Therapeutics has a consensus price target of $21.00, signalling upside risk potential of 13536.36%. On the other hand Actinium Pharmaceuticals has an analysts' consensus of $5.00 which suggests that it could grow by 252.11%. Given that Aptevo Therapeutics has higher upside potential than Actinium Pharmaceuticals, analysts believe Aptevo Therapeutics is more attractive than Actinium Pharmaceuticals.
Company Buy Ratings Hold Ratings Sell Ratings APVOAptevo Therapeutics0 0 0 ATNMActinium Pharmaceuticals2 1 0 -
Is APVO or ATNM More Risky?
Aptevo Therapeutics has a beta of 5.759, which suggesting that the stock is 475.852% more volatile than S&P 500. In comparison Actinium Pharmaceuticals has a beta of -0.271, suggesting its less volatile than the S&P 500 by 127.061%.
-
Which is a Better Dividend Stock APVO or ATNM?
Aptevo Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Actinium Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Aptevo Therapeutics pays -- of its earnings as a dividend. Actinium Pharmaceuticals pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios APVO or ATNM?
Aptevo Therapeutics quarterly revenues are --, which are smaller than Actinium Pharmaceuticals quarterly revenues of $81K. Aptevo Therapeutics's net income of -$6.4M is higher than Actinium Pharmaceuticals's net income of -$15.9M. Notably, Aptevo Therapeutics's price-to-earnings ratio is -- while Actinium Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Aptevo Therapeutics is 0.01x versus -- for Actinium Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income APVOAptevo Therapeutics0.01x -- -- -$6.4M ATNMActinium Pharmaceuticals-- -- $81K -$15.9M
-
Which has Higher Returns APVO or NBY?
NovaBay Pharmaceuticals has a net margin of -- compared to Aptevo Therapeutics's net margin of -49.65%. Aptevo Therapeutics's return on equity of -- beat NovaBay Pharmaceuticals's return on equity of -461.38%.
Company Gross Margin Earnings Per Share Invested Capital APVOAptevo Therapeutics-- -$87.80 -- NBYNovaBay Pharmaceuticals65.26% $1.42 $1.1M -
What do Analysts Say About APVO or NBY?
Aptevo Therapeutics has a consensus price target of $21.00, signalling upside risk potential of 13536.36%. On the other hand NovaBay Pharmaceuticals has an analysts' consensus of $0.85 which suggests that it could grow by 40.31%. Given that Aptevo Therapeutics has higher upside potential than NovaBay Pharmaceuticals, analysts believe Aptevo Therapeutics is more attractive than NovaBay Pharmaceuticals.
Company Buy Ratings Hold Ratings Sell Ratings APVOAptevo Therapeutics0 0 0 NBYNovaBay Pharmaceuticals1 0 0 -
Is APVO or NBY More Risky?
Aptevo Therapeutics has a beta of 5.759, which suggesting that the stock is 475.852% more volatile than S&P 500. In comparison NovaBay Pharmaceuticals has a beta of 0.427, suggesting its less volatile than the S&P 500 by 57.305%.
-
Which is a Better Dividend Stock APVO or NBY?
Aptevo Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NovaBay Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Aptevo Therapeutics pays -- of its earnings as a dividend. NovaBay Pharmaceuticals pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios APVO or NBY?
Aptevo Therapeutics quarterly revenues are --, which are smaller than NovaBay Pharmaceuticals quarterly revenues of $2.4M. Aptevo Therapeutics's net income of -$6.4M is lower than NovaBay Pharmaceuticals's net income of $7.7M. Notably, Aptevo Therapeutics's price-to-earnings ratio is -- while NovaBay Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Aptevo Therapeutics is 0.01x versus 0.16x for NovaBay Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income APVOAptevo Therapeutics0.01x -- -- -$6.4M NBYNovaBay Pharmaceuticals0.16x -- $2.4M $7.7M
-
Which has Higher Returns APVO or NNVC?
Nanoviricides has a net margin of -- compared to Aptevo Therapeutics's net margin of --. Aptevo Therapeutics's return on equity of -- beat Nanoviricides's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital APVOAptevo Therapeutics-- -$87.80 -- NNVCNanoviricides-- -$0.14 -- -
What do Analysts Say About APVO or NNVC?
Aptevo Therapeutics has a consensus price target of $21.00, signalling upside risk potential of 13536.36%. On the other hand Nanoviricides has an analysts' consensus of -- which suggests that it could grow by 364.29%. Given that Aptevo Therapeutics has higher upside potential than Nanoviricides, analysts believe Aptevo Therapeutics is more attractive than Nanoviricides.
Company Buy Ratings Hold Ratings Sell Ratings APVOAptevo Therapeutics0 0 0 NNVCNanoviricides0 0 0 -
Is APVO or NNVC More Risky?
Aptevo Therapeutics has a beta of 5.759, which suggesting that the stock is 475.852% more volatile than S&P 500. In comparison Nanoviricides has a beta of 0.913, suggesting its less volatile than the S&P 500 by 8.749%.
-
Which is a Better Dividend Stock APVO or NNVC?
Aptevo Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Nanoviricides offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Aptevo Therapeutics pays -- of its earnings as a dividend. Nanoviricides pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios APVO or NNVC?
Aptevo Therapeutics quarterly revenues are --, which are smaller than Nanoviricides quarterly revenues of --. Aptevo Therapeutics's net income of -$6.4M is lower than Nanoviricides's net income of -$2.2M. Notably, Aptevo Therapeutics's price-to-earnings ratio is -- while Nanoviricides's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Aptevo Therapeutics is 0.01x versus -- for Nanoviricides. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income APVOAptevo Therapeutics0.01x -- -- -$6.4M NNVCNanoviricides-- -- -- -$2.2M
-
Which has Higher Returns APVO or OGEN?
Oragenics has a net margin of -- compared to Aptevo Therapeutics's net margin of --. Aptevo Therapeutics's return on equity of -- beat Oragenics's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital APVOAptevo Therapeutics-- -$87.80 -- OGENOragenics-- -$3.60 -- -
What do Analysts Say About APVO or OGEN?
Aptevo Therapeutics has a consensus price target of $21.00, signalling upside risk potential of 13536.36%. On the other hand Oragenics has an analysts' consensus of $1.00 which suggests that it could grow by 640.82%. Given that Aptevo Therapeutics has higher upside potential than Oragenics, analysts believe Aptevo Therapeutics is more attractive than Oragenics.
Company Buy Ratings Hold Ratings Sell Ratings APVOAptevo Therapeutics0 0 0 OGENOragenics0 1 0 -
Is APVO or OGEN More Risky?
Aptevo Therapeutics has a beta of 5.759, which suggesting that the stock is 475.852% more volatile than S&P 500. In comparison Oragenics has a beta of 0.938, suggesting its less volatile than the S&P 500 by 6.243%.
-
Which is a Better Dividend Stock APVO or OGEN?
Aptevo Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Oragenics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Aptevo Therapeutics pays -- of its earnings as a dividend. Oragenics pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios APVO or OGEN?
Aptevo Therapeutics quarterly revenues are --, which are smaller than Oragenics quarterly revenues of --. Aptevo Therapeutics's net income of -$6.4M is lower than Oragenics's net income of -$2.2M. Notably, Aptevo Therapeutics's price-to-earnings ratio is -- while Oragenics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Aptevo Therapeutics is 0.01x versus 1.30x for Oragenics. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income APVOAptevo Therapeutics0.01x -- -- -$6.4M OGENOragenics1.30x -- -- -$2.2M
-
Which has Higher Returns APVO or TOVX?
Theriva Biologics has a net margin of -- compared to Aptevo Therapeutics's net margin of --. Aptevo Therapeutics's return on equity of -- beat Theriva Biologics's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital APVOAptevo Therapeutics-- -$87.80 -- TOVXTheriva Biologics-- -$1.55 -- -
What do Analysts Say About APVO or TOVX?
Aptevo Therapeutics has a consensus price target of $21.00, signalling upside risk potential of 13536.36%. On the other hand Theriva Biologics has an analysts' consensus of $7.00 which suggests that it could grow by 1527.91%. Given that Aptevo Therapeutics has higher upside potential than Theriva Biologics, analysts believe Aptevo Therapeutics is more attractive than Theriva Biologics.
Company Buy Ratings Hold Ratings Sell Ratings APVOAptevo Therapeutics0 0 0 TOVXTheriva Biologics1 1 0 -
Is APVO or TOVX More Risky?
Aptevo Therapeutics has a beta of 5.759, which suggesting that the stock is 475.852% more volatile than S&P 500. In comparison Theriva Biologics has a beta of 0.848, suggesting its less volatile than the S&P 500 by 15.165%.
-
Which is a Better Dividend Stock APVO or TOVX?
Aptevo Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Theriva Biologics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Aptevo Therapeutics pays -- of its earnings as a dividend. Theriva Biologics pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios APVO or TOVX?
Aptevo Therapeutics quarterly revenues are --, which are smaller than Theriva Biologics quarterly revenues of --. Aptevo Therapeutics's net income of -$6.4M is lower than Theriva Biologics's net income of -$4.3M. Notably, Aptevo Therapeutics's price-to-earnings ratio is -- while Theriva Biologics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Aptevo Therapeutics is 0.01x versus 0.33x for Theriva Biologics. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income APVOAptevo Therapeutics0.01x -- -- -$6.4M TOVXTheriva Biologics0.33x -- -- -$4.3M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will Google Stock Double by 2030?
If you bought Alphabet (NASDAQ: GOOGL) when Gmail launched in…
Why Did David Tepper Sell NVIDIA Stock?
In Q1, billionaire David Tepper of Appaloosa Management sold nearly…
Stock Ideas
Buy
65
Is NVDA Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 54x
Buy
67
Is MSFT Stock a Buy?
Market Cap: $3.7T
P/E Ratio: 42x
Sell
45
Is AAPL Stock a Buy?
Market Cap: $3T
P/E Ratio: 33x
Alerts
Sell
49
NKE alert for Jun 28
Nike [NKE] is up 15.29% over the past day.
Buy
81
KTOS alert for Jun 28
Kratos Defense & Security Solutions [KTOS] is up 10.89% over the past day.
Sell
44
GDXU alert for Jun 28
MicroSectors Gold Miners 3X Leveraged ETN [GDXU] is down 10.89% over the past day.
